[Bisphosphonates first-line pharmacological treatment]

Lakartidningen. 2016 Nov 1:113:D9H7.

[Article in Swedish]

Authors

Märit Wallander¹, Östen Ljunggren², Mattias Lorentzon³

Affiliations

¹ Karolinska University Hospital - Department of Endocrinology Stockholm, Sweden Karolinska University Hospital - Department of Endocrinology Stockholm, Sweden.
² Uppsala universitet - institutionen för medicinska vetenskaper Uppsala, Sweden - , Sweden.
³ Osteoporosmottagningen - Geriatriska kliniken, Sahlgrenska universitetssjukhset, Mölndal Mölndal, Sweden Geriatric Medicine - Institute of Medicine Mölndal, Sweden.

PMID: 27824394

No abstract available

Publication types

Review

MeSH terms

Bone Density Conservation Agents* / administration & dosage
Bone Density Conservation Agents* / adverse effects
Bone Density Conservation Agents* / therapeutic use
Calcium / administration & dosage
Calcium / therapeutic use
Denosumab / administration & dosage
Denosumab / therapeutic use
Diphosphonates* / administration & dosage
Diphosphonates* / adverse effects
Diphosphonates* / therapeutic use
Humans
Infusions, Intravenous
Osteoporosis / drug therapy*
Teriparatide / administration & dosage
Teriparatide / therapeutic use
Vitamin D / administration & dosage
Vitamin D / therapeutic use

Substances

Bone Density Conservation Agents
Diphosphonates
Teriparatide
Vitamin D
Denosumab
Calcium